Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;10(9):2270.
doi: 10.3390/biomedicines10092270.

Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation

Wern Yew Ding  1 , Ian G Davies  2 , Dhiraj Gupta  1 , Gregory Y H Lip  1   3
Affiliations

Relationship between Renal Function, Fibrin Clot Properties and Lipoproteins in Anticoagulated Patients with Atrial Fibrillation

Wern Yew Ding et al. Biomedicines. .

Abstract

Background: Mechanisms by which chronic kidney disease (CKD) influences fibrin clot properties in atrial fibrillation (AF) remain ill-defined. We aimed to investigate the effects of AF and CKD on fibrin clot properties and lipoproteins, and determine the relationship between these factors. Methods: Prospective cross-sectional study of patients recruited from cardiology services in Liverpool between September 2019 and October 2021. Primary groups consisted of anticoagulated AF patients with and without CKD in a 1:1 ratio. Control group comprised anticoagulated patients without AF or CKD. Fibrin clot properties were analysed using turbidity and permeation assays. Detailed lipoprotein characteristics, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), small dense LDL and oxidised LDL, were measured. Results: Fifty-six anticoagulated patients were enrolled (median age 72.5; 34% female); 46 with AF (23 with CKD and 23 without CKD) and 10 controls. AF was associated with changes in three indices of fibrin clot properties using PTT (Tlag 314 vs. 358 s, p = 0.047; Abspeak 0.153 vs. 0.111 units, p = 0.031; Tlysis50% 884 vs. 280 s, p = 0.047) and thrombin reagents (Tlag 170 vs. 132 s, p = 0.031; Tmax 590 vs. 462 s, p = 0.047; Tpeak50% 406 vs. 220 s, p = 0.005) while the concomitant presence of CKD led to changes in fibrin clot properties using kaolin (Tlag 1072 vs. 1640 s, p = 0.003; Tmax 1458 vs. 1962 s, p = 0.005; Tpeak50% 1294 vs. 2046, p = 0.008) and PPP reagents (Tlag 566 vs. 748 s, p = 0.044). Neither of these conditions were associated with changes in fibrin clot permeability. Deteriorating eGFR was significantly correlated to the speed of clot formation, and CKD was independently associated with unfavourable clot properties (Tlag -778, p = 0.002; Tmax -867, p = 0.004; Tpeak50% -853, p = 0.004 with kaolin reagent). AF alone was not associated with changes in lipoprotein distribution while AF patients with CKD had lower total cholesterol, LDL-C and small dense LDL due to the presence of other risk factors. No significant relationship was observed between fibrin clot properties and lipoprotein distribution. Conclusions: There are important changes that occur in fibrin clot properties with AF and CKD that may account for the increased risk of thromboembolic complications. However, these changes in fibrin clot properties were not attributable to alterations in lipoprotein distribution.

Keywords: chronic kidney disease; low-density lipoprotein; oxidised low-density lipoprotein; small dense low-density lipoprotein; turbidimetry.

PubMed Disclaimer

Conflict of interest statement

D.G.: Speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Biosense Webster and Boston Scientific. Proctor for Abbott. Research grants from Medtronic, Biosense Webster and Boston Scientific. G.Y.H.L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally. Other authors declare no conflict of interest.

References

    1. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., Gillum R.F., Kim Y.-H., McAnulty J.H.J., Zheng Z.-J., et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. doi: 10.1161/CIRCULATIONAHA.113.005119. - DOI - PMC - PubMed
    1. Benjamin E.J., Wolf P.A., D’Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation. 1998;98:946–952. doi: 10.1161/01.CIR.98.10.946. - DOI - PubMed
    1. Stewart S., Hart C.L., Hole D.J., McMurray J.J. A Population-Based Study of the Long-Term Risks Associated with Atrial Fibrillation: 20-Year Follow-up of the Renfrew/Paisley Study. Am. J. Med. 2002;113:359–364. doi: 10.1016/S0002-9343(02)01236-6. - DOI - PubMed
    1. Thrall G., Lane D., Carroll D., Lip G.Y.H. Quality of Life in Patients with Atrial Fibrillation: A Systematic Review. Am. J. Med. 2006;119:e1–e19. doi: 10.1016/j.amjmed.2005.10.057. - DOI - PubMed
    1. Vermond R.A., Geelhoed B., Verweij N., Tieleman R.G., Van der Harst P., Hillege H.L., Van Gilst W.H., Van Gelder I.C., Rienstra M. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality A Community-Based Study From the Netherlands. J. Am. Coll. Cardiol. 2015;66:1000–1007. doi: 10.1016/j.jacc.2015.06.1314. - DOI - PubMed

LinkOut - more resources